Startup accelerator empowers EFA to expand commercial sales.
(Courtesy of EFA) eHealth Ventures proudly announces its continued partnership with EFA Technologies together with international and local investors.
Imagine a world where you can walk into your local GPs office or pharmacy, take a small prick of blood, and get your Complete Blood Count (CBC) results instantly. With the new solution developed by EFA technologies, this future reality has already arrived.
Patients, worldwide, can face difficulties when trying to access adequate healthcare facilities equipped with CBC testing capabilities. This leads to limited options when it comes to diagnostic services, resulting in delayed diagnosis and treatment.
Israeli startup EFA Technologies is addressing this exact problem with their fully automated portable blood testing lab – RexDx. Under the leadership of CEO Yoel Ezra, the vision of EFA Technologies is to bring access to healthcare by providing affordable blood testing with immediate results.
If a symptomatic patient walks into the doctor’s office, there is not always enough information to know if the patient has an infection and needs antibiotics or if it is a virus that will pass on its own. CBC blood results are important because they enable doctors to make decisions on the spot without delaying treatment.
With the RevDx, CBC results are given immediately, allowing physicians to make instantaneous decisions based on clinical results, instead of waiting days or longer for blood work results to be processed and for patients to start the antibiotics.
While the general public could benefit from the cost and time savings of immediate clinical results at the doctor’s office, the greatest impact could be felt by remote locations, community health clinics, underserved communities and others.
EFA Technologies’ point-of-care CBC testing devices are portable and easy to use, enabling healthcare providers to perform tests anywhere. Weighing in at around fivepounds, the RevDx analyzes a small sample of the patient’s blood taken from the finger. EFA Technologies, which has CE approval and ANVISA regulatory approval in Brazil, has just closed a Series A round and initiated their commercial sales in Latin America, where their product will be used in different clinics around the country.
“We’re thrilled to witness the impact of RevDx’s on healthcare,” saysCEO Yoel Ezra on his excitement over the RevDx potential. “Our mission to make Medtech accessible to everybody, anywhere,starting with a complete blood count test (CBC), is coming to fruition. We’re dedicated to further expanding our reach for the benefit of patients and caregivers worldwide. Entering the vast and promising Brazilian market is a testament to that.”
EFA Technologies is backed by Israeli VC eHealth Ventures. By focusing on affordability and scalability, EFA Technologies ensures that its blood testing solutions are accessible to communities worldwide, regardless of economic status. Through their innovative solutions and commitment to improving healthcare systems around the world, EFA Technologies strives to ensure that every individual has access to essential diagnostic services.
